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Introduction: Neuroendocrine (NE) breast cancers encompass a heterogeneous group of tumours
showing morphological features similar to those of NE neoplasms of the gut and lung and expressing one
or more neuroendocrine markers (neuron speciﬁc enolase, chromogranins synaptophysin) in at least 50%
of tumour cells. They are rare lesions representing about 2–3% of all breast cancers and affecting more
frequently elderly patients.
Aim: Prospective observational study is to analyse the clinico-pathological aspects of NE carcinomas of
the breast undergone surgical resection compared to breast carcinomas with a minor neuroendocrine
component and to conventional invasive ductal or lobular cancers.
Material and method: Thirty-ﬁve consecutive breast carcinomas showing morphological features
suggestive of an endocrine differentiation were selected among breast cancers undergone surgical
treatment during the period of January 1979–December 2004.
Results: The 35 patients were divided into two categories: 13 neuroendocrine carcinomas (NECs) and 22
ductal carcinomas with a minor neuroendocrine component (DC-NE). The average follow-up was 60
months. The patients with CNE developed breast cancer in an advanced age compared to the patients
with inﬁltrating ductal carcinoma NAS or inﬁltrating lobular carcinoma. We did not ﬁnd recurrent
disease in the NEC group, while it was observed in 2 patients (9%) with DC-NE, in 6 cases (17%) with
inﬁltrating ductal carcinoma NAS and in 7 cases (20%) with inﬁltrating lobular carcinoma.
Discussion: The CNE compared with the inﬁltrating ductal and lobular carcinoma are statistically
different in relation to the expression of the receptor of c-erb-B2, p53, progesterone, for the lymph node
state at diagnosis and the risk of reappearance of breast tumour. Our study conﬁrms the choice to
consider the neuroendocrine carcinoma of the breast as a separate histological group and seems to
suggest a less aggressiveness of this type of tumour.
 2008 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Neuroendocrine (NE) breast cancers encompass a heteroge-
neous group of tumours showing morphological features similar to
those of NE neoplasms of the gut and lung and expressing one or
more neuroendocrine markers (neuron speciﬁc enolase, chro-
mogranins synaptophysin) in at least 50% of tumour cells. They are
rare lesions representing about 2–3% of all breast cancers and
affecting more frequently elderly patients (WHO 2003). Although
in themajority of cases NE carcinomas are endocrinologically silent,
rare cases with symptoms correlated to ectopic secretion of ACTH,
parathyroid hormone, calcitonin and norepinephrine have beenRovera).
ciates Ltd. Published by Elsevier Ltdescribed. Breast carcinomas showing focal endocrine differentia-
tion, revealed by immunohistochemical expression of neuroendo-
crine markers in scattered tumour cells, are not included in this
group.
Although the ﬁrst description of two breast cancers showing
morphological features resembling those of intestinal carcinoids
was published in 1963,1 the term ‘‘primary carcinoid tumour’’ of the
breast was introduced by Cubilla and Woodruff in 1977 to charac-
terize a group of tumours regarded as a new pathologic entity.2
Since those descriptions, several attempts have beenmade to better
characterize this particular tumour type, the existence of which and
methods for recognizing have been a highly controversial issue
over the past decade. It has been only recently deﬁnitively accepted
as a separate entity, but the term ‘‘breast carcinoid’’ has been
abandoned and the term ‘‘neuroendocrine carcinoma’’ is preferred
(WHO, 2003).d. All rights reserved.
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Cubilla and Woodruff, although failed to detect argyrophilic gran-
ules in the normal breast epithelium, concluded that neuroendo-
crine neoplasms derived from argyrophilic cells of neural crest
origin, presumably migrated to mammary ducts. However, this
embryology-derived theoryhas notbeendeﬁnitivelydemonstrated.
In 1985 Bussolati and co-workers identiﬁed, using immunohisto-
chemistry, the presence of chromogranin positive neuroendocrine
cells in normal ductal cells.3 However, other authors4 did not
conﬁrm this ﬁnding, so the presence of neuroendocrine cells in
normalmammaryducts has tobedeﬁnitivelyascertained todate.An
alternative hypothesis suggests that these tumors may originate
from epithelial cells that, during the carcinogenesis process, acquire
the ability to differentiate, focally or diffusely, toward an endocrine
line.5 This hypothesis could be indirectly conﬁrmed by the fact that
the existence of hyperplastic lesions or benign neuroendocrine
tumours of themammaryglandhas never beendemonstrated in the
breast, conversely to other system like the gastrointestinal tract.6
Furthermore, the existence of a double exocrine–endocrine differ-
entiation within neoplastic cells supports the hypothesis of
a common origin from a stemmammary cell.7
As proposed in the last WHO classiﬁcation of breast tumours
(2003), NE carcinomas are divided in three categories: (1) solid
neuroendocrine carcinoma, (2) small cells carcinoma, (3) large cells
carcinoma.
2. Aim
The aim of this prospective observational study was to analyse
the clinico-pathological aspects of NE carcinomas of the breast
undergone surgical resection and to compare them with those of
breast carcinomas with a minor neuroendocrine component and
with those of conventional invasive ductal or lobular cancers.
3. Material and methods
Thirty-ﬁve consecutive breast carcinomas showing morpho-
logical features suggestive of an endocrine differentiation were
selected, after morphological review, among breast cancers
undergone surgical treatment at the Department of Surgical
Sciences – University of Insubria in Varese during the period of
January 1979–December 2004. Clinical data were registered in
a computerized data-base. For comparison 35 consecutive cases of
inﬁltrating ductal breast cancers NAS and 35 cases of inﬁltrating
lobular carcinomas were also included in the study.
The selected cases of suspected NE carcinomas were immuno-
histochemically investigated to search for the expression of
neuroendocrine markers, including neuron speciﬁc enolase, syn-
aptophysin, chromogranin A, and CD56. In addition, all cases were
studied for the expression of oestrogen and progesterone receptors,
Ki67, p53 and c-erb-B2. The morphological study also included the
evaluation of cytological grade, vascular and neural invasion,
mitotic count, and morphological subtype according to Papotti
et al.8,9
4. Results
On the basis of the immunohistochemical results, the 35
selected carcinomas presenting morphological characteristics
suggestive for a neuroendocrine differentiation have been divided
into two categories:
- 13 neuroendocrine carcinomas (NECs) showing the expression
of at least one neuroendocrine marker in more than 50% of the
tumour cells. According to the WHO classiﬁcation all caseswere classiﬁed as solid neuroendocrine carcinomas. The
average age of patients was 79.8 years (range: 54–95 years).
About 70% of these tumours were well differentiated (G1) and
vascular invasion was demonstrated in 23% of cases.
- 22 ductal carcinomaswith aminor neuroendocrine component
(DC-NE), in which the expression of neuroendocrine markers
was found in less than 50% of the tumour cells. The average age
of patients was 79.4 years (range: 59–95 years) and vascular
invasion was observed in 5 cases on 22 (22.7%).
The average follow-up was 60 months with an interval range
between 24 and 120 months. Six patients (3 belonging to the NEC
category and 3 to that of DC-NE) died for causes not directly related
to the breast pathology; three patients were lost to follow-up as
living in provinces far fromVarese; one patient with DC-NE died for
disease 33months after surgery. Six patients (2 NECs and 4 DC-NEs)
developed bone metastases diagnosed 34 and 58 months, respec-
tively, after the diagnosis of breast cancer; in one patient (DC-NE)
breast cancer was locally advanced with signs of skin inﬁltration
(pT4b). We did not ﬁnd a statistically signiﬁcant different survival
(p¼ 0.06) between patients with NECs and those with DC-NEs.
The expression of oestrogen receptors was observed in the
majority of cells of all NECs (mean value of the cells expressing the
receptor: 91.5%) and of all DC-NEs (mean value: 81.7%); in addition,
the expression of the progesterone receptors was demonstrated in
all cases of both categories with a mean value of 76.4% and 51%,
respectively. Nuclear immunoreactivity for p53was found in 2 of 13
NECs (15%) and 3 of 22 cases of CD-NE (13.6%). The Ki67 prolifer-
ation index ranged in both groups between 1 and 25% (mean value:
14%). The c-erb-B2 membrane receptor immunoreactivity was not
found in any case.
Regarding the clinical aspects we observed that the patients
with CNE developed breast cancer in an advanced age compared to
the patients with inﬁltrating ductal carcinoma NAS or inﬁltrating
lobular carcinoma. Ipsilateral axillary lymph node involvement
(pNþ) was observed in 2 patients (15%) with NEC, in 4 (18%) with
DC-NE, in 10 (28.5%) with inﬁltrating ductal carcinoma NAS, and in
8 patients (23%) with inﬁltrating lobular carcinoma. This difference
was statistically signiﬁcant (p¼ 0.01). In addition, tumour
resumption during the follow-up periodwas statistically signiﬁcant
when comparing the NEC group with the other histological types
(p¼ 0.009). In details, we did not ﬁnd recurrent disease in the NEC
group, while it was observed in 2 patients (9%) with DC-NE, in 6
cases (17%) with inﬁltrating ductal carcinoma NAS and in 7 cases
(20%) with inﬁltrating lobular carcinoma. Conversely, among
various tumour groups there were not statistically signiﬁcant
differences in relation to diameter (p¼ 1), the expression of oes-
trogens receptors (p¼ 0.58) and Ki67proliferative index (p¼ 0.86).
5. Discussion
Although the existence of NECs of the breast and methods for
recognizing have been a highly controversial issue over the past
decade, the 2003 WHO classiﬁcation of tumours of the breast
legitimated this particular breast tumour type as a independent
category. The diagnosis is based on a typical neuroendocrine
morphology and on the expression of a neuroendocrine marker in
more than 50% of cells.
Based on the results of our observational prospective study, the
CNE compared with the inﬁltrating ductal and lobular carcinoma
are statistically different in relation to the expression of the
receptor of c-erb-B2, p53, progesterone, for the lymph node state at
diagnosis and the risk of reappearance of breast tumour. These
results conﬁrm the choice to consider the neuroendocrine carci-
noma of the breast as a separate histological group and seem to
F. Rovera et al. / International Journal of Surgery 6 (2008) S113–S115 S115suggest a less aggressiveness of the this type of tumour. The follow-
up data show that patients with NEC of non-small cell type have
a good survival. The overall survival of patients affected by NEC, in
our study, has turned out to be better than that of patients affected
by inﬁltrating ductal or lobular carcinoma. On the other hand, we
did not observe a statistically signiﬁcant difference between the
survival rate of patients with NEC and those with DC-NE, although
this data could be affected by the scarcity of the enrolled
population.Conﬂict of interest statement
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